Company Product Description Indication Status
Phase III
Sol-Gel Technologies Ltd., of Ness Ziona, Israel Twyneo Combination of microencapsulated tretinoin 0.1% and microencapsulated benzoyl peroxide 3% cream Acne vulgaris Demonstrated statistically significant improvement on all co-primary endpoints, including proportion of patients who achieved at least a 2-grade reduction from baseline and clear (grade 0) or almost clear (grade 1) at week 12 on a 5-point Investigator Global Assessment scale; an absolute change from baseline in inflammatory lesion count at week 12; and an absolute change from baseline in non-inflammatory lesion count at week 12

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments